🇺🇸 FDA

Intelligence · Clinical Pipeline

Novartis India Pipeline

All ClinicalTrials.gov programs at Novartis India — phase, modality, and trial IDs.

Programs
145

Quick answer

Novartis India has 145 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. -, -, ERYTHROPOIETIN , DANAZOL , VAY736, -, ENTECAVIR , Placebo to VAY736 150 mg/1 mL concentrate for solution for infusion, -, -

    Novartis Pharmaceuticals

    warm autoimmune haemolytic anaemia (wAIHA)

    phase 3 small molecule active

    1 trial

  2. -, DOCETAXEL , JDQ443

    Novartis Pharmaceuticals

    Advanced non-small cell lung cancer harboring the KRAS G12C mutation

    phase 3 small molecule active

    1 trial

  3. -, Placebo to ianalumab 150 mg/1 mL concentrate for solution for infusion, -, ENTECAVIR , -, ELTROMBOPAG, -, ELTROMBOPAG, ELTROMBOPAG, VAY736, -, ELTROMBOPAG

    Novartis Pharmaceuticals

    Primary immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  4. ABIRATERONE ACETATE, ABIRATERONE ACETATE, ENZALUTAMIDE, ABIRATERONE ACETATE, Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation, ENZALUTAMIDE, ENZALUTAMIDE

    Novartis Pharmaceuticals

    PSMA-positive metastatic castration-resistant prostate cancer

    phase 3 small molecule active

    1 trial

  5. ACZ885

    Novartis Pharmaceuticals

    Muckle Wells Syndrome

    phase 3 small molecule completed

    1 trial

  6. AIN457

    Novartis Pharmaceuticals

    Non-infectious Uveitis

    phase 3 mab terminated

    1 trial

  7. AIN457 150 mg

    Novartis Pharmaceuticals

    Moderate to Severe Chronic Plaque-Type Psoriasis

    phase 3 small molecule completed

    1 trial

  8. ALPELISIB, FULVESTRANT, ALPELISIB, Placebo to BYL719 50 mg film-coated tablet Light pink Placebo to BYL719 200 mg film-coated tablet Light red

    Novartis Pharmaceuticals

    Hormone receptor positive, HER2-negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  9. ASCIMINIB HYDROCHLORIDE, ASCIMINIB

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia in chronic phase (CML-CP)

    phase 3 small molecule active

    1 trial

  10. ATORVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, Placebo to KJX839 (Inclisiran), ATORVASTATIN, INCLISIRAN, ATORVASTATIN, ATORVASTATIN

    Novartis Pharmaceuticals

    Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or non-ST-elevation myocardial infarction [NSTEMI]) of recent onset.

    phase 3 small molecule active

    1 trial

  11. Aliskiren

    Novartis Pharmaceuticals

    Acute Decompensated Heart Failure

    phase 3 small molecule completed

    1 trial

  12. Asciminib

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia

    phase 3 small molecule completed

    1 trial

  13. BAF312, FINGOLIMOD HYDROCHLORIDE, BAF312, BAF312, Placebo to Ofatumumab (OMB157) [Kesimpta], BAF312, OFATUMUMAB, BAF312, Placebo to Siponimod (BAF312) [Mayzent] film-coated tablets, Placebo to Fingolimod (FTY720) [Gilenya] 0.25mg & 0.5mg, FINGOLIMOD HYDROCHLORIDE

    Novartis Pharmaceuticals

    Multiple Sclerosis in pediatric patients

    phase 3 small molecule active

    1 trial

  14. BYL719, BYL719, Placebo to BYL719 125 mg film-coated tablets, Placebo to BYL719 200 mg film-coated tablets, Placebo to BYL719 50 mg film-coated tablets, BYL719, BYL719, BYL719

    Novartis Pharmaceuticals

    lymphatic malformations associated with PIK3CA mutation

    phase 3 small molecule active

    1 trial

  15. Bion 1301/FUB523

    Novartis Pharmaceuticals

    IgA nephropathy

    phase 3 small molecule active

    1 trial

  16. CANAKINUMAB, PEMETREXED

    Novartis Pharmaceuticals

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  17. CPI-0610, CPI-0610

    Novartis Pharmaceuticals

    Myelofibrosis, Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia)

    phase 3 small molecule active

    1 trial

  18. Capmatinib

    Novartis Pharmaceuticals

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule terminated

    1 trial

  19. DASATINIB, IMATINIB, BOSUTINIB, DASATINIB, NILOTINIB, BOSUTINIB, DASATINIB, DASATINIB, NILOTINIB, DASATINIB, IMATINIB, IMATINIB, DASATINIB, ASCIMINIB HYDROCHLORIDE

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  20. DEXAMETHASONE , FLUDARABINE , CISPLATIN , OXALIPLATIN , CARBOPLATIN , LENALIDOMIDE , RITUXIMAB , TOCILIZUMAB , CYCLOPHOSPHAMIDE , BENDAMUSTINE , TISAGENLECLEUCEL, IFOSFAMIDE , MELPHALAN , CYTARABINE , CARMUSTINE , IBRUTINIB , ETOPOSIDE , GEMCITABINE

    Novartis Pharmaceuticals

    Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

    phase 3 small molecule active

    1 trial

  21. Dabrafenib

    Novartis Pharmaceuticals

    Malignant Melanoma

    phase 3 small molecule completed

    1 trial

  22. Deferasirox

    Novartis Pharmaceuticals

    Transfusion-dependent Iron Overload

    phase 3 small molecule completed

    1 trial

  23. ENTECAVIR , VAY736, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled syringe, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled pen, TENOFOVIR ALAFENAMIDE , -, VAY736, TENOFOVIR DISOPROXIL

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  24. EVEROLIMUS

    Novartis Pharmaceuticals

    Refractory seizures associated with tuberous sclerosis complex

    phase 3 small molecule active

    1 trial

  25. Everolimus

    Novartis Pharmaceuticals

    Advanced NET of GI Origin

    phase 3 small molecule completed

    1 trial

  26. Fingolimod

    Novartis Pharmaceuticals

    Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  27. Flucelvax Tetra - suspension for injection in pre-filled syringe Influenza vaccine (surface antigen, inactivated, prepared in cell cultures), PNEUMOVAX solution injectable en flacon Vaccin pneumococcique polyosidique, Pneumovax 23 oldatos injekció előretöltött fecskendőben Pneumococcus-poliszacharid vakcina, BOOSTRIX, suspension injectable en seringue préremplie Vaccin diphtérique, tétanique et coquelucheux (acellulaire multicomposé), (adsorbé, à teneur réduite en antigènes), Pneumovax 23 oldatos injekció e

    Novartis Pharmaceuticals

    Relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  28. Fulvestrant

    Novartis Pharmaceuticals

    Metastatic Breast Cancer

    phase 3 small molecule terminated

    1 trial

  29. Fulvestrant

    Novartis Pharmaceuticals

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  30. GOSERELIN, RIBOCICLIB, ANASTROZOLE, LETROZOLE

    Novartis Pharmaceuticals

    hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC).

    phase 3 small molecule active

    1 trial

  31. Gilenya 0.5 mg hard capsules, Gilenya 0.25 mg hard capsules

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  32. Glycopyrronium bromide

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    1 trial

  33. INCLISIRAN, -

    Novartis Pharmaceuticals

    Familial hypercholsterolemia

    phase 3 small molecule active

    1 trial

  34. INCLISIRAN, KJX839, Placebo to KJX839 (Inclisiran) 0 mg/1.5 mL Solution for injection in vial

    Novartis Pharmaceuticals

    homozygous familial hypercholesterolemia

    phase 3 small molecule active

    1 trial

  35. INCLISIRAN, KJX839, Placebo to KJX839 (Inclisiran) 0 mg/1.5 mL Solution for injection in vial

    Novartis Pharmaceuticals

    Heterozygous Familial Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  36. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  37. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical hemolytic uremic syndrome

    phase 3 small molecule active

    1 trial

  38. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  39. IPTACOPAN HYDROCHLORIDE

    Novartis Pharmaceuticals

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  40. IPTACOPAN, LNP023

    Novartis Pharmaceuticals

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  41. Ianalumab

    Novartis Pharmaceuticals

    Primary Immune Thrombocytopenia (ITP)

    phase 3 mab active

    1 trial

  42. Ianalumab

    Novartis Pharmaceuticals

    Primary Immune Thrombocytopenia

    phase 3 mab active

    2 trials

  43. Inclisiran

    Novartis Pharmaceuticals

    Familial Hypercholesterolemia - Heterozygous

    phase 3 small molecule completed

    1 trial

  44. Indacaterol 150 μg

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    2 trials

  45. Indacaterol 150 μg

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule completed

    1 trial

  46. Investigators choice of SoC

    Novartis Pharmaceuticals

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  47. Iptacopan

    Novartis Pharmaceuticals

    Atypical Hemolytic Uremic Syndrome

    phase 3 small molecule completed

    1 trial

  48. JDQ443

    Novartis Pharmaceuticals

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does Novartis India have?

145 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.